$51.17
0.62% yesterday
Nasdaq, Jul 29, 10:00 pm CET
ISIN
US6047491013
Symbol
MIRM

Mirum Pharmaceuticals Inc Stock price

$51.17
+0.28 0.55% 1M
+2.57 5.29% 6M
+9.82 23.75% YTD
+9.12 21.69% 1Y
+26.07 103.86% 3Y
+30.91 152.57% 5Y
+37.96 287.36% 10Y
+37.96 287.36% 20Y
Nasdaq, Closing price Tue, Jul 29 2025
-0.32 0.62%
ISIN
US6047491013
Symbol
MIRM
Industry

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$2.6b
Net debt
$30.8m
Cash
$277.7m
Shares outstanding
49.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.7 | 5.5
EV/Sales
6.8 | 5.6
EV/FCF
negative
P/B
10.9
Financial Health
Equity Ratio
33.6%
Return on Equity
-39.0%
ROCE
-13.6%
ROIC
-
Debt/Equity
1.3
Financials (TTM | estimate)
Revenue
$379.3m | $460.7m
EBITDA
$-52.3m | $-48.3m
EBIT
$-76.3m | $-61.2m
Net Income
$-77.3m | $-56.1m
Free Cash Flow
$-27.9m
Growth (TTM | estimate)
Revenue
69.3% | 36.8%
EBITDA
63.3% | 24.5%
EBIT
51.6% | 30.2%
Net Income
51.2% | 36.3%
Free Cash Flow
33.7%
Margin (TTM | estimate)
Gross
77.1%
EBITDA
-13.8% | -10.5%
EBIT
-20.1%
Net
-20.4% | -12.2%
Free Cash Flow
-7.4%
More
EPS
$-1.6
FCF per Share
$-0.6
Short interest
13.3%
Employees
322
Rev per Employee
$1.1m
Show more

Is Mirum Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Mirum Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

Buy
94%
Hold
6%

Financial data from Mirum Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
379 379
69% 69%
100%
- Direct Costs 87 87
45% 45%
23%
292 292
78% 78%
77%
- Selling and Administrative Expenses 214 214
33% 33%
57%
- Research and Development Expense 154 154
39% 39%
41%
-52 -52
63% 63%
-14%
- Depreciation and Amortization 24 24
59% 59%
6%
EBIT (Operating Income) EBIT -76 -76
52% 52%
-20%
Net Profit -77 -77
51% 51%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Mirum Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mirum Pharmaceuticals Inc Stock News

Neutral
Business Wire
19 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Positive
Investors Business Daily
about one month ago
Biotech stock Mirum Pharmaceuticals has rocketed 236% since its IPO in 2019. Shares are near a buy point after earnings.
Neutral
Business Wire
about 2 months ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
More Mirum Pharmaceuticals Inc News

Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Head office United States
CEO Christopher Peetz
Employees 322
Founded 2018
Website mirumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today